A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2

Frederick J Meyers, Carolyn Paradise, Sidney A Scudder, Gary Goodman, Michael Konrad

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

A more soluble formulation of recombinant interleukin-2 with a prolonged half-life would allow alternate routes or schedules of administration and enhance patient comfort. The covalent attachment of polyethylene glycol to recombinant interleukin-2 provides an analog with deal data suggesting those desired characteristics while maintaining biologic activity. This is the report of a phase 1 study in which we sought to determine the maximum tolerated dose of polyethylene glycol interleukin-2, observe biologic activity, and confirm the prolonged half-life in vivo. Sixty-six patients were entered into the study during 19 months. Polyethylene glycol interleukin-2 was administered intravenously once a week over 15 minutes. The maximum tolerated dose was 20 × 106 U/M2 The pattern of toxicity was quite similar to that of the parent compound. Four patients had evidence of tumor regression (three partial remission; one minor response). The pharmaeokinetic data confirmed a 10- to 20-fold prolongation in half-life compared with recombinant interleukin-2. No neutralizing antibodies were detected. This study provides sufficient impetus for the ongoing phase II studies of polyethylene glycol interleukin-2.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume49
Issue number3
StatePublished - Mar 1991

Fingerprint

Interleukin-2
Pharmacokinetics
Half-Life
Maximum Tolerated Dose
Neutralizing Antibodies
Appointments and Schedules
Neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. / Meyers, Frederick J; Paradise, Carolyn; Scudder, Sidney A; Goodman, Gary; Konrad, Michael.

In: Clinical Pharmacology and Therapeutics, Vol. 49, No. 3, 03.1991, p. 307-313.

Research output: Contribution to journalArticle

@article{9a82c4afb7d145e7b1957d01ffd2b786,
title = "A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2",
abstract = "A more soluble formulation of recombinant interleukin-2 with a prolonged half-life would allow alternate routes or schedules of administration and enhance patient comfort. The covalent attachment of polyethylene glycol to recombinant interleukin-2 provides an analog with deal data suggesting those desired characteristics while maintaining biologic activity. This is the report of a phase 1 study in which we sought to determine the maximum tolerated dose of polyethylene glycol interleukin-2, observe biologic activity, and confirm the prolonged half-life in vivo. Sixty-six patients were entered into the study during 19 months. Polyethylene glycol interleukin-2 was administered intravenously once a week over 15 minutes. The maximum tolerated dose was 20 × 106 U/M2 The pattern of toxicity was quite similar to that of the parent compound. Four patients had evidence of tumor regression (three partial remission; one minor response). The pharmaeokinetic data confirmed a 10- to 20-fold prolongation in half-life compared with recombinant interleukin-2. No neutralizing antibodies were detected. This study provides sufficient impetus for the ongoing phase II studies of polyethylene glycol interleukin-2.",
author = "Meyers, {Frederick J} and Carolyn Paradise and Scudder, {Sidney A} and Gary Goodman and Michael Konrad",
year = "1991",
month = "3",
language = "English (US)",
volume = "49",
pages = "307--313",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2

AU - Meyers, Frederick J

AU - Paradise, Carolyn

AU - Scudder, Sidney A

AU - Goodman, Gary

AU - Konrad, Michael

PY - 1991/3

Y1 - 1991/3

N2 - A more soluble formulation of recombinant interleukin-2 with a prolonged half-life would allow alternate routes or schedules of administration and enhance patient comfort. The covalent attachment of polyethylene glycol to recombinant interleukin-2 provides an analog with deal data suggesting those desired characteristics while maintaining biologic activity. This is the report of a phase 1 study in which we sought to determine the maximum tolerated dose of polyethylene glycol interleukin-2, observe biologic activity, and confirm the prolonged half-life in vivo. Sixty-six patients were entered into the study during 19 months. Polyethylene glycol interleukin-2 was administered intravenously once a week over 15 minutes. The maximum tolerated dose was 20 × 106 U/M2 The pattern of toxicity was quite similar to that of the parent compound. Four patients had evidence of tumor regression (three partial remission; one minor response). The pharmaeokinetic data confirmed a 10- to 20-fold prolongation in half-life compared with recombinant interleukin-2. No neutralizing antibodies were detected. This study provides sufficient impetus for the ongoing phase II studies of polyethylene glycol interleukin-2.

AB - A more soluble formulation of recombinant interleukin-2 with a prolonged half-life would allow alternate routes or schedules of administration and enhance patient comfort. The covalent attachment of polyethylene glycol to recombinant interleukin-2 provides an analog with deal data suggesting those desired characteristics while maintaining biologic activity. This is the report of a phase 1 study in which we sought to determine the maximum tolerated dose of polyethylene glycol interleukin-2, observe biologic activity, and confirm the prolonged half-life in vivo. Sixty-six patients were entered into the study during 19 months. Polyethylene glycol interleukin-2 was administered intravenously once a week over 15 minutes. The maximum tolerated dose was 20 × 106 U/M2 The pattern of toxicity was quite similar to that of the parent compound. Four patients had evidence of tumor regression (three partial remission; one minor response). The pharmaeokinetic data confirmed a 10- to 20-fold prolongation in half-life compared with recombinant interleukin-2. No neutralizing antibodies were detected. This study provides sufficient impetus for the ongoing phase II studies of polyethylene glycol interleukin-2.

UR - http://www.scopus.com/inward/record.url?scp=0026061242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026061242&partnerID=8YFLogxK

M3 - Article

C2 - 2007324

AN - SCOPUS:0026061242

VL - 49

SP - 307

EP - 313

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -